WASHINGTON, April 10, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its 5.00% Series B Mandatory Convertible Preferred Stock (the "Preferred Stock"), will automatically convert into shares of the Company's common stock on April 17, 2023 (the "Conversion Date"). The conversion rate for each share of Preferred Stock will be 5.0175 shares of the Company's common stock. Cash will be paid in lieu of fractional shares of common stock.
As previously announced, on April 17, 2023 holders of record at the close of business on March 31, 2023 will separately receive a final quarterly cash dividend of $12.50 per share on the Preferred Stock. As the last dividend payment date of April 15, 2023 falls on a Saturday, the dividend will be paid the following business day, on April 17, 2023.
ABOUT DANAHER
Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world. Its family of world class brands has leadership positions in the demanding and attractive health care, environmental and applied end-markets. With more than 20 operating companies, Danaher's globally diverse team of approximately 81,000 associates is united by a common culture and operating system, the Danaher Business System, and its Shared Purpose, Helping Realize Life's Potential. For more information, please visit www.danaher.com.
Last Trade: | US$192.97 |
Daily Change: | 4.24 2.25 |
Daily Volume: | 3,859,831 |
Market Cap: | US$139.380B |
February 25, 2025 February 20, 2025 January 29, 2025 January 21, 2025 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load